Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jul 1:14:2789-2795.
doi: 10.2147/RMHP.S314451. eCollection 2021.

Extrapyramidal Side Effects in a Patient with Alcohol Withdrawal Symptoms: A Reflection of Quality of the Mental Health Care System

Affiliations
Case Reports

Extrapyramidal Side Effects in a Patient with Alcohol Withdrawal Symptoms: A Reflection of Quality of the Mental Health Care System

Mark Mohan Kaggwa et al. Risk Manag Healthc Policy. .

Abstract

Background: The burden of substance use disorders is increasing in most countries in sub-Saharan Africa. Individuals with substance use disorders (eg, alcohol use disorder) are at high risk of manifesting extrapyramidal side effects or extrapyramidal symptoms (EPS) during treatment of alcohol-induced mental illness symptoms especially psychosis. EPS management poses a challenge since some of the drugs used for treating EPS have addictive properties. The knowledge about EPS diagnosis and treatment is not well distributed across the health system, with health workers at lower health facilities having least awareness. The present case gives details of a patient who developed EPS during the management of alcohol withdrawal symptoms.

Case details: Following cessation of alcohol use, a 54-year-old man with alcohol use disorder presented with a one-week history of visual, auditory and tactile hallucinations, illusions, insomnia, extreme fear and irritability. He was managed with several daily doses of intramuscular chlorpromazine 100 mg, whenever he woke up aggressive from sedation from a peripheral health facility. Four days after his admission, he became mute, stiff, immobile, triple-flexed, tremulous and was drooling saliva. He was referred to a secondary facility for further management while on antipsychotic medication. Finally, he was referred to a tertiary facility, managed with tablets of benzhexol 5 mg twice daily and intravenous diazepam 20 mg per day. Daily follow-up was done using the extrapyramidal symptom rating scale (ESRS) for EPS. EPS symptoms resolved ten days after initiation of treatment.

Conclusion: EPS among individuals with addictive disorders poses a challenge in its management, especially in countries where the mental health care system is not well developed at lower-level health facilities. The mental health system has to prepare sustainable interventions to properly manage EPS among the growing population of individuals with addictive disorders through strengthening the mental health policy by training and equipping all health providers with knowledge and skills in managing EPS, increasing finances allocated for mental health and controlling the production and use of addictive substances.

Keywords: Akandi; EPS; Uganda; addiction; alcohol use disorder; extrapyramidal side effects; mental health system; typical antipsychotics; withdrawal symptoms.

PubMed Disclaimer

Conflict of interest statement

The authors reported no conflicts of interest for this work.

References

    1. Abu-Naser D, Gharaibeh S, Al Meslamani AZ, Alefan Q, Abunaser R. Assessment of extrapyramidal symptoms associated with psychotropics pharmacological treatments, and associated risk factors. Clin Pract Epidemiol Mental Health. 2021;17:1. doi: 10.2174/1745017902117010001 - DOI - PMC - PubMed
    1. D’Souza RS, Hooten WM. Extrapyramidal Symptoms. StatPearls [Internet]; 2020. - PubMed
    1. Li HC, Luo KX, Wang JS, Wang QX. Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: a case report. Medicine. 2020;99(11). - PMC - PubMed
    1. Pierre JM. Abuse of psychiatric medications: not just stimulants and benzodiazepines. Curr Psychiatr. 2019;18(1):11.
    1. Hedenmalm K, Güzey C, Dahl ML, Yue QY, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol. 2006;26(2):192–197. doi: 10.1097/01.jcp.0000203200.96205.34 - DOI - PubMed

Publication types

LinkOut - more resources